Overview
- Fiscal Q4 revenue rose 17% to $99.01 million, topping estimates, while the GAAP loss was $0.45 per share, slightly wider than consensus.
- Gross margin improved to 51.3% and the adjusted EBITDA loss narrowed to $7.8 million from $17 million a year ago.
- Fiscal 2026 sales are guided to $425–$435 million, with gross margin expected above 52% and adjusted EBITDA breakeven targeted in Q4.
- First-quarter 2026 sales are projected at $100–$101 million, roughly in line with Street expectations.
- Operational scale expanded in 2025 with about 938,000 genes shipped to roughly 3,800 customers, as the stock traded down about 11% and William Blair reiterated Outperform.